Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Country | Information available on substances listed in categories "Miscellaneous" and "Other" | |
---|---|---|
Belgium | Tablets containing mCPP are included in the category "miscellaneous". In 2009 most "miscellaneous" records contained mCPP (alone or in combination with other substance) | |
Bulgaria | In category "miscellaneous" most of the cases concerned forms of CPP, barbiturates and benzodiazepine derivates. Category "others" includes tablets containing 2C-B and GHB. | |
Czech Republic | : | |
Denmark | Tablets in the category "other" are mainly mCPP, alone or in combination with other substances. The 77% breakdown as follow: 17% mCPP; 2% mCPP + MDMA; 48% mCPP + amphetamine; 7% 2C-B; 1% 2C-I ; 1% PCP + methamphetamine. Tablets in the category "miscellaneous" are caffeine and/or ephedrine. | |
Germany | Tablets included in the category "others" only contain mCPP. | |
Estonia | Tablets included in the category "others" only contain 4-CPP. | |
Ireland | : | |
Greece | No information is available due that neither categories, "miscellaneous" nor "others", represent more than 5% of the records. | |
Spain | The category "miscellaneous" includes mainly benzodiazepines, ketamine and DOB. | |
France-A | Tablets containing mCPP - 4-fluoroamphetamine are included in the category "miscellaneous". | |
France-B | Tablets containing mCPP are included in the category "miscellaneous". | |
Italy | Category "Miscellaneous" includes mainly mCPP ( 96%). Category "Other" refers to LSD stamps. | |
Cyprus | Tablets in the category "others" (71.7%) breakdown as follow: 87.9% BZP+TMPP+DBZP and 5.6% mCPP and "miscellaneous": 6.5% methandrostenolone. | |
Latvia | No information available. | |
Lithuania | : | |
Luxembourg | Tablets in the category "other / miscellaneous" are mainly caffeine, paracetamol and ibuprofen. | |
Hungary | Tablets in the category "others" (11.6%) breakdown as follow: 8.68% BZP, 1.65% GHB and 1.24% 2C-B . The 33.5 % into the category "miscellaneous" breakdown as follow: 28.10% mCPP, 3.31% MDPV, 1.24% 4-FA , 0.41% butylone and 0.41% ketamine+mCPP. | |
Malta | : | |
Netherlands | Tablets in the category "miscellaneous" are mainly mCPP (12%) and mephedrone (7%). | |
Austria | Tablets containing mCPP are included in the category "miscellaneous". In 2009 the 3.51% in the category "others" breakdown as follow: PMA n=3; methcathinone n=1 and the 76.32% in the category "miscellaneous" breakdown as follow: mCPP+metoclopramide n=15; mCPP+unknown substance(s) n=11; mCPP n=31; fenproporex n=1; unknown substance(s) n=28; unknown substance +TFMPP n=1. | |
Poland | No information available. | |
Portugal | Tablets in the category "miscellaneous" (95.81%) breakdowns as follow: 5 records of BZP (70.98 %), 33 records of mCPP (4%), 5 records of 2C-B (0.55%) and 1 record of Piperonal (24.38%); BZP= 17051 tablets, mCPP= 983 tablets, 2C-B= 131 tablets and Piperonal= 5856 tablets. | |
Romania | : | |
Slovenia-A | : | |
Slovenia-B | : | |
Slovakia | Tablets included in the category "miscellaneous" only contain mCPP. | |
Finland | Tablets included in the category "miscellaneous" contain mainly mCPP and TFMPP+BZP. | |
Sweden | : | |
United Kingdom | Tablets in the category "miscellaneous" are piperazine type tablets (BZP, TFMPP and CPP). | |
Croatia | Tablets in the category "miscellaneous" are mCPP alone and in combination with traces of MDMA, amphetamine, TFMPP or parafluoroamphetamine and in the category "others" are 2C-B, 4-bromo-2,5-dimethoxyphenethylamine and controlled substance in combination with mCPP. | |
Turkey | Tablets included in the category "miscellaneous" contain: MDMA+mCPP, MDMA+mCPP+caffeine, benzodiazepines (clonazepam and alprazolam) and biperidene. | |
Norway | No information available. |
(see the help page for information about formats etc.)
Page last updated: Wednesday, 22 June 2011